ArticleJournal of asthma and allergy2022
Real-World Clinical Outcomes in Asthmatic Patients Switched from Omalizumab to Anti-Interleukin-5 Therapy.
Article in Journal of asthma and allergy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Biologic Switching in Patients with Severe Asthma: Effects on Exacerbations, Corticosteroid Use and Lung Function.Journal of clinical medicine · 2026Article
- Choosing and switching biologics for patients with severe asthma: Real-world data from the German Asthma Net (GAN).Allergologie select · 2026Article
- Advancing Care in Severe Asthma: The Art of Switching Biologics.Advances in respiratory medicine · 2024Review
- Japanese Patients with Severe Asthma Identified as Responders to Omalizumab Treatment at 2 Years Based on the GETE Score Continued Treatment for an Extended Period.Journal of asthma and allergy · 2024Article
- Switching Biological Therapies in Severe Asthma.International journal of molecular sciences · 2023Review
- Real-World clinical outcomes of asthma patients switched from reslizumab to mepolizumab or benralizumab.Frontiers in allergy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.